The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1275 articles
For patients battling cancer with brain metastases and type 2 diabetes, GLP-1 receptor agonists may offer a survival edge. A retrospective study of over 19,000 patients found GLP-1 RA users had significantly lower all-cause mortality (HR 0.63) after matching. This benefit held across major cancers and most GLP-1 RA types.
A quote from The Economist's Style Guide warns against calling anything a panacea—yet GLP-1 drugs for type 2 diabetes and obesity are now eyed by healthy individuals for longevity. Is their time as a miracle cure finally here? This guide weighs the excitement against expert caution and real-world considerations.
A groundbreaking study reveals Wegovy carries a fivefold higher risk of vision-threatening ischemic optic neuropathy compared to Ozempic. Analyzing millions of FDA reports, researchers link the risk to semaglutide's higher doses in Wegovy. Amid rising lawsuits, patients need to weigh benefits against potential eye health dangers.
Weight loss injections such as Mounjaro and Wegovy, popular GLP-1 inhibitors, come with side effects impacting one in 10 users, primarily digestive issues like nausea and diarrhea. The British Heart Foundation highlights risks including pancreatitis, vision loss, and nutritional deficiencies. Understanding these helps patients manage treatment safely.
A surge in dieting demand has triggered shortages of Mounjaro's 5mg starting dose, making it hard for metabolic disease patients to access treatment. Clinics in Seoul report instability until late March, as non-reimbursed status leaves supply unmanaged. Patients like Mr. A face halted therapy despite proven benefits for diabetes control and weight loss.
DJ Shimza sets the record straight on trending rumors about his rapid weight loss and career perks. He denies using Ozempic, crediting exercise, diet overhaul, and supplements instead. Amid speculation, he remains open to others using GLP-1 meds like Ozempic.
At 67, Bobbi Parker-Hall microdoses Ozempic not for dramatic weight loss, but for metabolic stability and surprising intimacy benefits like multiple orgasms. She shares how low-dose semaglutide, paired with strength training, keeps her lean and vibrant post-menopause. Here's what her story reveals about this trending approach.
Demi Moore turned heads at the South By Southwest festival premiere of 'I Love Boosters!' with her strikingly slim silhouette, accentuated by a daring sleeveless wrap dress. This follows her lean look at the Actor Awards, sparking widespread online speculation about Ozempic use. While unverified, the buzz highlights growing interest in GLP-1 medications like Ozempic for weight loss.
Persistence rates for GLP-1 medications like semaglutide and tirzepatide in patients without diabetes seeking weight loss have nearly doubled over the past five years, jumping from 33.2% in 2021 to 60.9% in mid-2024. New research highlights improved adherence, the role of drug switching, and factors like resolved supply shortages driving these gains. These trends offer hope for long-term obesity management.
